Article
Unoprostone lowers IOP in advanced glaucoma cases
Washington, DC-Unoprostone isopropyl 0.15% (Rescula, Novartis) may be a viable option for further lowering IOP in patients with advanced glaucoma whose disease is uncontrolled by maximum tolerated medical therapy, said Leslie S. Jones, MD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
